Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0YTRFZ
ADC Name	Vandortuzumab vedotin
Synonyms	Anti-STEAP1-vc-MMAE; RG-7450; DSTP-3086S; DSTP3086S Click to Show/Hide
Organization	Genentech, Inc.; Roche Holding AG; Agensys, Inc.; Astellas Pharma, Inc.
Drug Status	Terminated in phase 1
Indication	In total 1 Indication(s) Prostate cancer [ICD11:2C82] Terminated in phase 1
Drug-to-Antibody Ratio	3-4
Structure
	3D MOL	2D MOL
Antibody Name	Vandortuzumab		Antibody Info
Antigen Name	Metalloreductase STEAP1 (STEAP1)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Vedotin
Puchem SID	381127541 , 472408348 , 336908617 , 350078340 , 476262854 , 476269400
ChEBI ID	CHEMBL3833306

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Partial Response (PR)	NCT01283373	Phase 1	A phase 1, open-label study of the safety and pharmacokinetics of escalating doses of DSTP3086S in patients with metastatic castration-resistant prostate cancer.
Undisclosed	NCT01283373	Phase 1	A phase 1, open-label study of the safety and pharmacokinetics of escalating doses of DSTP3086S in patients with metastatic castration-resistant prostate cancer.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Partial Response (PR)	4.00%
Patients Enrolled	Metastatic castration-resistant prostate cancer (CRPC).
Administration Dosage	3 + 3 dose escalation study, 0.30 to 2.80 mg/kg intravenously given once every 3 weeks followed by cohort expansion at the recommended phase II dose or weekly (0.80 to 1.00 mg/kg).
*Related Clinical Trial*
NCT Number	NCT01283373	Clinical Status	Phase 1
Clinical Description	A phase 1, open-label study of the safety and pharmacokinetics of escalating doses of DSTP3086S in patients with metastatic castration-resistant prostate cancer.
Primary Endpoint	DsTP3086S has acceptable safety at the recommended phase II dose level of 2.40 mg/kg once every 3 weeks.
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT01283373	Clinical Status	Phase 1
Clinical Description	A phase 1, open-label study of the safety and pharmacokinetics of escalating doses of DSTP3086S in patients with metastatic castration-resistant prostate cancer.

References

Ref 1	Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019 Dec 20;37(36):3518-3527.
Ref 2	A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer